Molecular therapy for Metastatic cancers: Ivermectin, the anthelmintic drug, increases the expression of metastasis suppressors  PTEN and PDCD4, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 19/August/2017, 12.40 am

Natural product-derived CMTM6/4-PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: A therapeutic mix encompassing Honokiol and Magnolol, isolated from Magnolia grandiflora/dealbata/obovata/officinalis, inhibits the expression of transmembrane protein CMTM6/CMTM4, increases interferon-IFNγ signalling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 19/August/2017, 11.58 pm
August 19, 2017
Natural product-based therapy for Inflammatory bowel disease(IBD): Mangiferin, isolated from Mangoes, decreases the expression of oncostatin M, attenuates activation of oncostatin M- oncostatin M receptor pathway in inflamed colon tissues, inhibits inflammatory gene expression, attenuates colonic pathogenesis, and inhibits the progression of inflammatory bowel disease and colitis via down regulation of its target gene, 20/August/2017, 12.56 am
August 19, 2017
Show all

From Significance of the study to Public health relevance:

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer patients die due to metastasis; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) bio-molecules that drive metastatic process; and the the way to prevent their expression; (ii) a way to activate immune system to combat cancer (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (ii) a side-effect-free natural product-based drug; (iii) increase the therapeutic index of anticancer drugs; and (iv) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


Research findings to Therapeutic opportunity: 

Ivermectin (Brand name: Heartguard/Mectizen)  has been shown to function as an anticancer agent (fig. 1). However, the detailed mechanistic insights is yet to emerge.

This study suggests that Ivermectin, by regulating the expression of its target genes, it may increase the expression of metastasis suppressors PTEN and PDCD4 (fig. 1).

[easy_payment currency=”USD”]

Thereby, it may: (a) inhibit cell cycle progression; and (d) suppress migration, invasion and metastasis of cancer cells. 

Thus,  Ivermectin-based treatment may be advised for metastatic cancer patients to (i) increase the expression of metastasis suppressor genes in tumors; (ii) inhibit the progression of metastatic tumors; and (ii) enhance the efficacy of Cancer therapy. Together, oncologists may consider experimenting the use of Ivermectin in the treatment of advanced metastatic cancers.


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $10#

Undisclosed mechanistic information: How Ivermectin increases the expression of metastasis suppressors PTEN and PDCD4

Fig1. Mechanistic insights into the anthelmintic drug Ivermectin functions as an anti-metastasis agent. Ivermectin increases the expression of metastasis suppressors PTEN and PDCD4 via down regulation of its target genes.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

CitationBoominathan, L., Molecular therapy for Metastatic cancers: Ivermectin, the anthelmintic drug, increases the expression of metastasis suppressors  PTEN and PDCD4, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 19/August/2017, 12.40 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.